Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Ann Surg Oncol. 2019 Nov 15;27(3):743–749. doi: 10.1245/s10434-019-08038-8

TABLE 3.

Multivariable Associations Between Patient and Disease Factors, and Mastectomy Group Among Those with Data on Imaging Response (n = 407)

OR odds ratio, CI confidence interval, ER estrogen receptor, PR progesterone receptor, BCT breast-conserving therapy, mammo mammogram, NAC neoadjuvant chemotherapy

Factor OR (95% CI) p-value
Age at surgery 0.92 (0.9–0.95) < .001
Stage 0.005
 1/2 1.00
 3 0.49 (0.3–0.81)
Subtype 0.014
 ER−, PR−, HER2− 1.00
 ER−, PR−, HER2+ 0.32 (0.14–0.72)
 ER/PR+, HER2− 0.46 (0.25–0.86)
 ER/PR+, HER2+ 0.74 (0.38–1.43)
Candidate BCT post-chemo 2.6 (1.56–4.34) < .001
Residual palpable disease 0.58 (0.34–0.98) 0.043
Positive clinical axillary nodes 1.23 (0.53–2.84) 0.627
Persistent abnormality on any imaging (mammo and/or MRI) post NAC 0.004
 No 1.00
 Yes 0.39 (0.21–0.74)